June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Pretreatment levels of vitreous protein biomarkers correlate with visual acuity outcome in response to intravitreal triamcinolone in Diabetic Macular Edema
Author Affiliations & Notes
  • Bert M Glaser
    The National Retina Institute, Towson, Maryland, United States
    Ocular Proteomics, LLC, Towson, Maryland, United States
  • Natsumi Takahashi
    Ocular Proteomics, LLC, Towson, Maryland, United States
  • Matthew S J Katz
    The National Retina Institute, Towson, Maryland, United States
  • Footnotes
    Commercial Relationships   Bert Glaser, None; Natsumi Takahashi, None; Matthew Katz, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2027. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Bert M Glaser, Natsumi Takahashi, Matthew S J Katz; Pretreatment levels of vitreous protein biomarkers correlate with visual acuity outcome in response to intravitreal triamcinolone in Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2027.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic macular edema (DME) is a complication of diabetes that can lead to blindness if left untreated. Currently there are no biomarkers available for prediction of treatment response in eyes with DME. In this study, we sought to identify vitreous protein biomarkers that correlate with the change in visual acuity in response to intravitreal injection of triamcinolone (Triesence®).

Methods : Vitreous aspirates (50-120μL) were obtained from patients treated for DME with intravitreal injection (Triesence®) in a study approved by the institutional review board. Vitreous samples were acquired immediately prior to intravitreal injection. 10 samples obtained from 9 eyes of 9 patients between 10/1/10 and 4/7/15 were analyzed by Reverse Phase Protein Microarray. The samples were tested for 76 different protein biomarkers. A linear regression analysis was performed to elucidate the relationship between the baseline (pretreatment) biomarker levels and the change in visual acuity at approximately 2-3 month (50-100days) after treatment.

Results : Out of 76 biomarkers, the baseline levels of 14 biomarkers, including p38 MAPK T180/Y182 and VEGF, were found to show statistically significant correlation (p < 0.0001) with the change in visual acuity at 50-100 days after treatment. These biomarkers were also highly predictive of the visual acuity outcome with R2 values ranging between 0.86 and 0.90.

Conclusions : Our results suggest that some protein biomarkers may be able to predict the visual acuity outcome in response to intravitreal injection of triamcinolone in eyes with DME. Further analysis of 14 biomarkers identified in this study is required to select a biomarker panel that can potentially be used in the management of DME.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×